JP2023536497A - 免疫原性化合物 - Google Patents

免疫原性化合物 Download PDF

Info

Publication number
JP2023536497A
JP2023536497A JP2023507480A JP2023507480A JP2023536497A JP 2023536497 A JP2023536497 A JP 2023536497A JP 2023507480 A JP2023507480 A JP 2023507480A JP 2023507480 A JP2023507480 A JP 2023507480A JP 2023536497 A JP2023536497 A JP 2023536497A
Authority
JP
Japan
Prior art keywords
asyn
disease
defined above
amino acid
antigenic peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023507480A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536497A5 (enExample
Inventor
ヴィンター，ドリアン
シュタッフラー，ギュンター
ガラボワ，ゲルガナ
ミハイロヴスカ，エヴァ
グルーバー，ペトラ
バラージュ，カッチャ
Original Assignee
エイシー イミューン ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エイシー イミューン ソシエテ アノニム filed Critical エイシー イミューン ソシエテ アノニム
Publication of JP2023536497A publication Critical patent/JP2023536497A/ja
Publication of JP2023536497A5 publication Critical patent/JP2023536497A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023507480A 2020-08-04 2021-08-04 免疫原性化合物 Pending JP2023536497A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20189425.0 2020-08-04
EP20189425 2020-08-04
PCT/EP2021/071778 WO2022029181A1 (en) 2020-08-04 2021-08-04 Immunogenic compounds

Publications (2)

Publication Number Publication Date
JP2023536497A true JP2023536497A (ja) 2023-08-25
JP2023536497A5 JP2023536497A5 (enExample) 2024-08-13

Family

ID=72178339

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507480A Pending JP2023536497A (ja) 2020-08-04 2021-08-04 免疫原性化合物

Country Status (10)

Country Link
US (1) US20230287050A1 (enExample)
EP (1) EP4192493A1 (enExample)
JP (1) JP2023536497A (enExample)
KR (1) KR20230044524A (enExample)
CN (1) CN116261464A (enExample)
AU (1) AU2021322080A1 (enExample)
CA (1) CA3185563A1 (enExample)
IL (1) IL300364A (enExample)
MX (1) MX2023001483A (enExample)
WO (1) WO2022029181A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240147981A (ko) * 2022-02-09 2024-10-10 에이씨 이뮨 에스에이 항-알파시누클레인 치료 백신
AU2024211543A1 (en) 2023-01-26 2025-07-17 Ac Immune Sa Liposomal construct
WO2025109524A1 (en) 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014528695A (ja) * 2011-06-23 2014-10-30 バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー 抗アルファシヌクレイン結合分子
JP2016216482A (ja) * 2008-02-22 2016-12-22 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ 神経変性疾患治療のためのαシヌクレインのミモトープ及びそれらのワクチン

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2361928T3 (pl) 2003-05-19 2017-09-29 Prothena Biosciences Limited Skrócone fragmenty alfa-synukleiny w chorobie z ciałami Lewy'ego
US20050203010A1 (en) 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
AT508638B1 (de) 2009-08-21 2011-08-15 Affiris Ag Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
RU2734924C2 (ru) 2015-11-03 2020-10-26 Аффирис Аг Способ вакцинации против аутоантигена у пациента-человека
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
EP3638298A4 (en) * 2017-06-16 2021-05-05 United Neuroscience PEPTIDE IMMUNOGENS FROM THE C-TERMINAL END OF ALPHA-SYNUCLEIN-PROTEIN AND FORMULATIONS THEREOF FOR THE TREATMENT OF SYNUCLEINOPATHIA
US20230074436A1 (en) * 2019-09-20 2023-03-09 Denali Therapeutics Inc. Anti-alpha-synuclein antibodies and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016216482A (ja) * 2008-02-22 2016-12-22 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ 神経変性疾患治療のためのαシヌクレインのミモトープ及びそれらのワクチン
JP2014528695A (ja) * 2011-06-23 2014-10-30 バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー 抗アルファシヌクレイン結合分子

Also Published As

Publication number Publication date
CA3185563A1 (en) 2022-02-10
WO2022029181A1 (en) 2022-02-10
KR20230044524A (ko) 2023-04-04
CN116261464A (zh) 2023-06-13
EP4192493A1 (en) 2023-06-14
IL300364A (en) 2023-04-01
AU2021322080A1 (en) 2023-02-23
MX2023001483A (es) 2023-03-08
US20230287050A1 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
US20250326806A1 (en) Compositions of Phosphorylated Tau Peptides and Uses Thereof
KR20110036809A (ko) 파킨슨병과 관련된 증상을 치료하기 위한 화합물
KR20110036808A (ko) 베타-아밀로이드증을 치료하기 위한 화합물
KR20110036039A (ko) 아밀로이드증을 치료하기 위한 화합물
US20070172496A1 (en) Conjugates of amyloid proteins as vaccines for amyloid-related diseases
JP2023536497A (ja) 免疫原性化合物
US20150306194A1 (en) Method for treating a synucleiopathy
CA3137884A1 (en) Heterologous administration of tau vaccines
US20250152684A1 (en) Anti-Alpha-Synuclein Therapeutic Vaccines
TW202438516A (zh) TAU及β類澱粉肽免疫原組合物及相關方法
EA048154B1 (ru) Иммуногенные соединения
HK40087814A (zh) 免疫原性化合物
TW202142551A (zh) 針對pcsk9胜肽免疫原及其預防和治療pcsk9介導疾病的製劑
EA051687B1 (ru) Терапевтические вакцины против альфа-синуклеина
CN118660717A (zh) 抗α-突触核蛋白的治疗性疫苗
HK40105209A (zh) 磷酸化tau肽的组合物及其用途
HK40039870A (en) Compositions of phosphorylated tau peptides and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240802

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250715

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251007

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260402